Post-results note
Progress still needs to become visible - Q1 review
Maria Karlsson Osipova
2026-05-20
06:25 CEST
After Q1, we still see the long-term equity story as intact, but we need to see the company deliver in the coming quarters – not just roadmaps and promises. We have revised our revenue and EBITDA forecasts, pushing revenue from the veterinary market one year forward. Our new fair value range is NOK0.2–0.6 (0.3–1.0) per share.
Q1 in numbers. Lifecare remains pre-commercial and reported NOK0.8m in revenue in Q1, almost entirely attributable to government grant recognition. Reported EBIT of cNOK-32m (down 26% Y/Y) was impacted by a NOK12m non-cash impairment related to Lifecare Germany. Excluding this, underlying EBIT was cNOK-20m, representing a c20% improvement in EBIT Y/Y. During the conference call, the company provided no detailed guidance regarding total opex, but the CEO noted that the company expects the wind-down of Lifecare Germany to lower the cost base in Q2–Q3 2026, with employee-related costs estimated to fall by 30–35% by Q3. During Q1, Lifecare raised cNOK100m and repaid NOK52m in bridge/shareholder loans. With a cash position of NOK26m at quarter’s end, the next focal point is the June warrant exercise.
Veterinary milestone. Lifecare's CE marking of the implant electronics is a positive step and, according to the company, enables the veterinary product to be cleared for commercial sales in Europe. However, our understanding is that veterinary commercialisation is strategically subordinate to the human development pathway. During the conference call, the company stated that it would be too optimistic to anticipate revenue from the veterinary market in H2 2026. We have therefore adjusted our revenue estimates and pushed vet revenue further out in time.
Management's pivot to a single-study CE mark strategy (replacing the prior two-step approach) is in our view positive, implying a simpler regulatory pathway and lower overall costs. However, no further details on the substance of the NOMA communication or timelines were provided. The company expects a full regulatory reassessment to conclude by mid-June 2026, with a detailed update planned in Q2 2026. After estimate revisions and with an updated share count, our new fair value range is NOK0.2-0.6 (0.3-1.0).